Kaftrio was licensed on 21st August 2020 and has been shown to improve both lung function, nutrition and overall symptoms of CF. We await NHS England guidance on the blood tests that will be needed and exactly which patients are eligible for this new treatment. We expect that approximately 300 people with CF attending our clinic will be able to trial this medication, which will be delivered to you via the homecare company Lloyds. As a team we shall prioritise people with poor lung function, followed by those patients who are not taking any kind of CFTR modulator (ie not on Orkambi, Symkevi or Kalydeco currently).
If you have any queries or concerns, please do not hesitate to contact us.
With best wishes to you all
Dr Joanna Whitehouse